LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will present an overview of the company at the following investor conferences during the month of September:
The conferences are being held in New York City.
A live webcast of each presentation will be accessible through the Investors section of the company’s website at www.amagpharma.com. Following each conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for approximately two weeks.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG manufactures and sells two commercial products, Feraheme® (ferumoxytol) Injection for intravenous (IV) use and GastroMARK®, an oral contrast agent used in magnetic resonance imaging. For additional company information, please visit www.amagpharma.com.
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361
KEYWORDS: United States North America Massachusetts New York
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Other Health Professional Services Finance